Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.

Mangia A, Piazzolla V, Giannelli A, Visaggi E, Minerva N, Palmieri V, Carraturo I, Potenza D, Napoli N, Lauletta G, Tagarielli V, Santoro R, Piccigallo E, De Gioia S, Chimenti A, Cuccorese G, Metrangolo A, Mazzola M, Agostinacchio E, Mennea G, Sabbà C, Cela M, Copetti M, Losappio R.

PLoS One. 2019 Sep 25;14(9):e0223287. doi: 10.1371/journal.pone.0223287. eCollection 2019.

2.

SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.

Mangia A, Piazzolla V, Giannelli A, Visaggi E, Minerva N, Palmieri V, Carraturo I, Potenza D, Napoli N, Lauletta G, Tagarielli V, Santoro R, Piccigallo E, De Gioia S, Chimenti A, Cuccorese G, Metrangolo A, Mazzola M, Agostinacchio E, Mennea G, Sabbà C, Cela M, Copetti M, Losappio R.

PLoS One. 2019 May 15;14(5):e0215783. doi: 10.1371/journal.pone.0215783. eCollection 2019. Erratum in: PLoS One. 2019 Sep 25;14(9):e0223287.

3.

Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras.

Peiffer KH, Kuhnhenn L, Stelzl E, Dietz J, Susser S, Tal AO, Finkelmeier F, Zuckerman E, Cornberg M, Barak M, Piazzolla V, Mangia A, Zeuzem S, Kessler HH, Vermehren J, Sarrazin C.

J Clin Microbiol. 2019 Jun 25;57(7). pii: e00060-19. doi: 10.1128/JCM.00060-19. Print 2019 Jul.

PMID:
31043467
4.

SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study.

Mangia A, Cenderello G, Copetti M, Verucchi G, Piazzolla V, Lorusso C, Santoro R, Squillante MM, Orlandini A, Minisini R, Ciancio A.

Cells. 2019 Apr 4;8(4). pii: E313. doi: 10.3390/cells8040313.

5.

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.

Boni C, Janssen HLA, Rossi M, Yoon SK, Vecchi A, Barili V, Yoshida EM, Trinh H, Rodell TC, Laccabue D, Alfieri A, Brillo F, Fisicaro P, Acerbi G, Pedrazzi G, Andreone P, Cursaro C, Margotti M, Santoro R, Piazzolla V, Brunetto MR, Coco B, Cavallone D, Zhao Y, Joshi A, Woo J, Lau AH, Gaggar A, Subramanian GM, Massetto B, Fung S, Ahn SH, Ma X, Mangia A, Ferrari C.

Gastroenterology. 2019 Jul;157(1):227-241.e7. doi: 10.1053/j.gastro.2019.03.044. Epub 2019 Mar 28.

PMID:
30930022
6.

Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus.

Vergara C, Thio CL, Johnson E, Kral AH, O'Brien TR, Goedert JJ, Mangia A, Piazzolla V, Mehta SH, Kirk GD, Kim AY, Lauer GM, Chung RT, Cox AL, Peters MG, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Busch MP, Alexander G, Rosen HR, Murphy EL, Latanich R, Wojcik GL, Taub MA, Valencia A, Thomas DL, Duggal P.

Gastroenterology. 2019 Apr;156(5):1496-1507.e7. doi: 10.1053/j.gastro.2018.12.014. Epub 2018 Dec 26.

PMID:
30593799
7.

TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.

Boni C, Vecchi A, Rossi M, Laccabue D, Giuberti T, Alfieri A, Lampertico P, Grossi G, Facchetti F, Brunetto MR, Coco B, Cavallone D, Mangia A, Santoro R, Piazzolla V, Lau A, Gaggar A, Subramanian GM, Ferrari C.

Gastroenterology. 2018 May;154(6):1764-1777.e7. doi: 10.1053/j.gastro.2018.01.030. Epub 2018 Jan 31.

PMID:
29378197
8.

"Five-A-Day" and the Med-Food Anticancer Program.

Piazzolla V, Panunzio MF, Caporizzi R, Cela EP, Di Martino V, Antoniciello A, Prato R, Germinario CA, Lagravinese D, Conversano M, Ferguson LR.

Ann Ig. 2018 Jan-Feb;30(1):73-74. doi: 10.7416/ai.2018.2199. No abstract available.

9.

Editorial: good news to patients with thalassaemia-HCV clearance made easy with direct acting antivirals. Authors' reply.

Mangia A, Piazzolla V, Santoro R.

Aliment Pharmacol Ther. 2017 Sep;46(6):629-630. doi: 10.1111/apt.14251. No abstract available.

10.

Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection.

Mangia A, Sarli R, Gamberini R, Piga A, Cenderello G, Piazzolla V, Santoro R, Caruso V, Quarta A, Ganga R, Copetti M, Forni G.

Aliment Pharmacol Ther. 2017 Aug;46(4):424-431. doi: 10.1111/apt.14197. Epub 2017 Jun 29.

11.

Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras.

Susser S, Dietz J, Schlevogt B, Zuckerman E, Barak M, Piazzolla V, Howe A, Hinrichsen H, Passmann S, Daniel R, Cornberg M, Mangia A, Zeuzem S, Sarrazin C.

J Hepatol. 2017 Oct;67(4):680-686. doi: 10.1016/j.jhep.2017.05.027. Epub 2017 Jun 13.

PMID:
28619439
12.

Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.

Mangia A, Susser S, Piazzolla V, Agostinacchio E, De Stefano G, Palmieri V, Spinzi G, Carraturo I, Potenza D, Losappio R, Arleo A, Miscio M, Santoro R, Sarrazin C, Copetti M.

J Hepatol. 2017 Apr;66(4):711-717. doi: 10.1016/j.jhep.2016.12.002. Epub 2016 Dec 10.

PMID:
27965158
13.

The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin.

Mangia A, Arleo A, Copetti M, Miscio M, Piazzolla V, Santoro R, Squillante MM.

Liver Int. 2016 Jul;36(7):971-6. doi: 10.1111/liv.13069. Epub 2016 Feb 7.

PMID:
26786792
14.

Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies.

Mangia A, Piazzolla V.

Dig Liver Dis. 2014 Dec 15;46 Suppl 5:S179-85. doi: 10.1016/j.dld.2014.09.026. Epub 2014 Oct 31. Review.

15.

Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience.

Mangia A, Cenderello G, Orlandini A, Piazzolla V, Picciotto A, Zuin M, Ciancio A, Brancaccio G, Forte P, Carretta V, Zignego AL, Minerva N, Brindicci G, Marignani M, Baroni GS, Bertino G, Cuccorese G, Mottola L, Ripoli M, Pirisi M.

PLoS One. 2014 Oct 23;9(10):e110284. doi: 10.1371/journal.pone.0110284. eCollection 2014.

16.

Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre study.

Mottola L, Cenderello G, Piazzolla VA, Forte P, Carretta V, Mecenate F, Brancaccio G, Minisini R, Zuin M, Terreni N, Monti M, Colombo AE, Nosotti L, Minerva N, Luzzitelli I, Kostandini A, Cuccorese G, Russello M, Santoro R, Mangia A.

Liver Int. 2015 Feb;35(2):482-8. doi: 10.1111/liv.12630. Epub 2014 Jul 17.

PMID:
25039676
17.

Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion-acquired HCV infection.

Zavaglia C, Silini E, Mangia A, Airoldi A, Piazzolla V, Vangeli M, Stigliano R, Foschi A, Mazzarelli C, Tinelli C.

Liver Int. 2014 Aug;34(7):e308-16. doi: 10.1111/liv.12502. Epub 2014 Mar 12.

PMID:
24529078
18.

Reply to: "Built-in bias in HCV clearance in acute HCV infection".

Copetti M, Pellegrini F, Piazzolla V, Mangia A.

J Hepatol. 2014 Feb;60(2):461-3. doi: 10.1016/j.jhep.2013.10.009. Epub 2013 Oct 23. No abstract available.

19.

Treatment optimization and prediction of HCV clearance in patients with acute HCV infection.

Mangia A, Santoro R, Copetti M, Massari M, Piazzolla V, Spada E, Cappucci G, Missale G, Mottola L, Agostinacchio E, Mauro Ld, Zuccaro O, Maio P, Pellegrini F, Folgori A, Ferrari C.

J Hepatol. 2013 Aug;59(2):221-8. doi: 10.1016/j.jhep.2013.04.007. Epub 2013 Apr 12.

PMID:
23587473
20.

Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution.

Arena U, Lupsor Platon M, Stasi C, Moscarella S, Assarat A, Bedogni G, Piazzolla V, Badea R, Laffi G, Marra F, Mangia A, Pinzani M.

Hepatology. 2013 Jul;58(1):65-72. doi: 10.1002/hep.26343. Epub 2013 May 27.

PMID:
23447459
21.

Update on the treatment of patients with non-genotype 1 hepatitis C virus infection.

Mangia A, Mottola L, Piazzolla V.

Clin Infect Dis. 2013 May;56(9):1294-300. doi: 10.1093/cid/cis1195. Epub 2012 Dec 27. Review.

PMID:
23271787
22.

IL28B CC-genotype association with HLA-DQB1*0301 allele increases the prediction of spontaneous HCV RNA clearance in thalassaemic HCV-infected patients.

Mangia A, Santoro R, Sarli R, Mottola L, Piazzolla V, Petruzzellis D, Bacca D, Clemente R, Copetti M, di Mauro L, Lotti G, Sacco M, Stefano I.

Antivir Ther. 2011;16(8):1309-16. doi: 10.3851/IMP1913.

PMID:
22155912
23.

Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring.

Mangia A, Thompson AJ, Santoro R, Piazzolla V, Copetti M, Minerva N, Petruzzellis D, Mottola L, Bacca D, McHutchison JG.

Hepatology. 2011 Sep 2;54(3):772-80. doi: 10.1002/hep.24458. Epub 2011 Jul 21.

PMID:
21626525
24.

Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, Patel K, Muir AJ, Shianna KV, Mottola L, Petruzzellis D, Romano M, Sogari F, Facciorusso D, Goldstein DB, McHutchison JG, Mangia A.

Hepatology. 2011 Feb;53(2):389-95. doi: 10.1002/hep.24068. Epub 2011 Jan 10.

25.

Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3.

Mangia A, Bandiera F, Montalto G, Mottola L, Piazzolla V, Minerva N, Pellicelli A, Ricci GL, Cela M, Carretta V, Scotto G, Bacca D, Annicchiarico B, Romano M, Russello M, Barbarini G, Agostinacchio E, Andriulli A.

J Hepatol. 2010 Dec;53(6):1000-5. doi: 10.1016/j.jhep.2010.04.042. Epub 2010 Aug 4.

PMID:
20843575
26.

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.

Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, McHutchison JG.

Gastroenterology. 2010 Sep;139(3):821-7, 827.e1. doi: 10.1053/j.gastro.2010.05.079. Epub 2010 Jun 2.

PMID:
20621700
27.

Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin.

Mangia A, Dalgard O, Minerva N, Verbaan H, Bacca D, Ring-Larsen H, Copetti M, Carretta V, Piazzolla V, Cozzolongo R, Mottola L, Andriulli A.

Aliment Pharmacol Ther. 2010 Jun;31(12):1346-53. doi: 10.1111/j.1365-2036.2010.04290.x. Epub 2010 Mar 8.

28.

[Basal plasma levels of insulin and C-peptide in 38-year-old women: comparison of randomized samples from northern and southern Europe].

Uleri S, Falcieri P, Zambelli L, Balzanelli M, Piazzolla V.

Medicina (Firenze). 1988 Apr-Jun;8(2):190-1. Italian. No abstract available.

PMID:
3067041

Supplemental Content

Loading ...
Support Center